-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JKkVTG2/lAL2QOq1L/+lbQrILRaxAvtubzzi1D/hSyYGsRx+6BPflgPQeebMvdhU /9Q/m9TseU3ztdh2LkBE/Q== 0001025894-02-000175.txt : 20020415 0001025894-02-000175.hdr.sgml : 20020415 ACCESSION NUMBER: 0001025894-02-000175 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020308 GROUP MEMBERS: DAVID NIERENBERG GROUP MEMBERS: HAREDALE, LTD. GROUP MEMBERS: JAMES HENRY HILDEBRANDT GROUP MEMBERS: THE D3 FAMILY FUND GROUP MEMBERS: THE DAVID AND PATRICIA NIERENBERG 1993 TRUST GROUP MEMBERS: TOXFORD CORPORATION FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: NIERENBERG DAVID CENTRAL INDEX KEY: 0001040899 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 19605 N E 8TH STREET CITY: CAMAS STATE: WA ZIP: 98607 BUSINESS PHONE: 3606048600 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NATUS MEDICAL INC CENTRAL INDEX KEY: 0000878526 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 770154833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-77922 FILM NUMBER: 02570941 BUSINESS ADDRESS: STREET 1: 1501 INDUSTRIAL ROAD CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 6508020400 MAIL ADDRESS: STREET 1: 1501 INDUSTRIAL ROAD CITY: SAN CARLOS STATE: CA ZIP: 94070 SC 13D 1 n_baby13.txt SCHEDULE 13D, BABY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ----- NATUS MEDICAL INCORPORATED (BABY) - -------------------------------------------------------------------------------- (Name of Issuer) COMMON - -------------------------------------------------------------------------------- (Title of Class of Securities) 639050103 ------------------------------ (CUSIP Number) David Nierenberg, The D3 Family Fund, 19605 NE 8th St., Camas, WA 98607 360-604-8600 ------------------------------------------------------------------------------ (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) 2/28/02 ------------------------------- (Date of Event which Requires Filing of this Statement) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1 of 14 SCHEDULE 13D ------------ CUSIP No. 639050103 Page 2 of 14 1) NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON The D3 Family Fund, L.P. -------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ X ] (b) [ ] 3) SEC USE ONLY -------------------------------------------------------------------------- 4) SOURCE OF FUNDS WC -------------------------------------------------------------------------- 5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] -------------------------------------------------------------------------- 6) CITIZENSHIP OR PLACE OF ORGANIZATION Washington State -------------------------------------------------------------------------- 7) SOLE VOTING POWER NUMBER OF 857,400 (5.4%) SHARES -------------------------------------------------- BENEFICIALLY 8) SHARED VOTING POWER OWNED BY 0 -------------------------------------------------- EACH 9) SOLE DISPOSITIVE POWER REPORTING 857,400 (5.4%) PERSON -------------------------------------------------- WITH 10) SHARED DISPOSITIVE POWER 0 -------------------------------------------------- 11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 929,968 -------------------------------------------------------------------------- 12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] -------------------------------------------------------------------------- 13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.9% -------------------------------------------------------------------------- 14) TYPE OF REPORTING PERSON* PN -------------------------------------------------------------------------- SCHEDULE 13D/A -------------- CUSIP No. 639050103 Page 3 of 14 1) NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Haredale, Ltd. -------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ X ] (b) [ ] 3) SEC USE ONLY -------------------------------------------------------------------------- 4) SOURCE OF FUNDS WC -------------------------------------------------------------------------- 5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] -------------------------------------------------------------------------- 6) CITIZENSHIP OR PLACE OF ORGANIZATION The Bahamas -------------------------------------------------------------------------- 7) SOLE VOTING POWER NUMBER OF 22,600 (0.1%) SHARES -------------------------------------------------- BENEFICIALLY 8) SHARED VOTING POWER OWNED BY 0 -------------------------------------------------- EACH 9) SOLE DISPOSITIVE POWER REPORTING 22,600 (0.1%) PERSON -------------------------------------------------- WITH 10) SHARED DISPOSITIVE POWER 0 -------------------------------------------------- 11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 929,968 shares -------------------------------------------------------------------------- 12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] -------------------------------------------------------------------------- 13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.9% -------------------------------------------------------------------------- 14) TYPE OF REPORTING PERSON* CO -------------------------------------------------------------------------- SCHEDULE 13D CUSIP No. 639050103 Page 4 of 14 1) NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON James Henry Hildebrandt -------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ X ] (b) [ ] -------------------------------------------------------------------------- 3) SEC USE ONLY -------------------------------------------------------------------------- 4) SOURCE OF FUNDS WC -------------------------------------------------------------------------- 5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] -------------------------------------------------------------------------- 6) CITIZENSHIP OR PLACE OF ORGANIZATION Canada -------------------------------------------------------------------------- 7) SOLE VOTING POWER NUMBER OF 10,700 (0.1%) SHARES -------------------------------------------------- BENEFICIALLY 8) SHARED VOTING POWER OWNED BY 0 -------------------------------------------------- EACH 9) SOLE DISPOSITIVE POWER REPORTING 10,700 (0.1%) PERSON -------------------------------------------------- WITH 10) SHARED DISPOSITIVE POWER 0 -------------------------------------------------- 11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 929,968 -------------------------------------------------------------------------- 12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] -------------------------------------------------------------------------- 13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.9% -------------------------------------------------------------------------- 14) TYPE OF REPORTING PERSON* IN -------------------------------------------------------------------------- SCHEDULE 13D CUSIP No. 639050103 Page 5 of 14 1) NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Toxford Corporation -------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ X ] (b) [ ] -------------------------------------------------------------------------- 3) SEC USE ONLY -------------------------------------------------------------------------- 4) SOURCE OF FUNDS WC -------------------------------------------------------------------------- 5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] -------------------------------------------------------------------------- 6) CITIZENSHIP OR PLACE OF ORGANIZATION The Channel Islands -------------------------------------------------------------------------- 7) SOLE VOTING POWER NUMBER OF 6,300 (0.0%) SHARES -------------------------------------------------- BENEFICIALLY 8) SHARED VOTING POWER OWNED BY 0 -------------------------------------------------- EACH 9) SOLE DISPOSITIVE POWER REPORTING 6,300 (0.0%) PERSON -------------------------------------------------- WITH 10) SHARED DISPOSITIVE POWER 0 -------------------------------------------------- 11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 929,968 -------------------------------------------------------------------------- 12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] -------------------------------------------------------------------------- 13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.9% -------------------------------------------------------------------------- 14) TYPE OF REPORTING PERSON* CO -------------------------------------------------------------------------- SCHEDULE 13D CUSIP No. 639050103 Page 6 of 14 1) NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON David Nierenberg -------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ X ] (b) [ ] -------------------------------------------------------------------------- 3) SEC USE ONLY -------------------------------------------------------------------------- 4) SOURCE OF FUNDS OO (Distribution from venture capital partnership.) -------------------------------------------------------------------------- 5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] -------------------------------------------------------------------------- 6) CITIZENSHIP OR PLACE OF ORGANIZATION USA -------------------------------------------------------------------------- 7) SOLE VOTING POWER NUMBER OF 2,111 (0.0%) SHARES -------------------------------------------------- BENEFICIALLY 8) SHARED VOTING POWER OWNED BY 0 -------------------------------------------------- EACH 9) SOLE DISPOSITIVE POWER REPORTING 2,111 (0.0%) PERSON -------------------------------------------------- WITH 10) SHARED DISPOSITIVE POWER 0 -------------------------------------------------- 11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 929,968 -------------------------------------------------------------------------- 12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] -------------------------------------------------------------------------- 13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.9% -------------------------------------------------------------------------- 14) TYPE OF REPORTING PERSON* IN -------------------------------------------------------------------------- SCHEDULE 13D CUSIP No. 639050103 Page 7 of 14 1) NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON The David and Patricia Nierenberg 1993 Irrevocable Trust, June 11, 1993, Lawrence K. Orr, Trustee -------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ X ] (b) [ ] -------------------------------------------------------------------------- 3) SEC USE ONLY -------------------------------------------------------------------------- 4) SOURCE OF FUNDS WC -------------------------------------------------------------------------- 5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] -------------------------------------------------------------------------- 6) CITIZENSHIP OR PLACE OF ORGANIZATION Washington -------------------------------------------------------------------------- 7) SOLE VOTING POWER NUMBER OF 30,857 (0.2%) SHARES -------------------------------------------------- BENEFICIALLY 8) SHARED VOTING POWER OWNED BY 0 -------------------------------------------------- EACH 9) SOLE DISPOSITIVE POWER REPORTING 30,857 (0.2%) PERSON -------------------------------------------------- WITH 10) SHARED DISPOSITIVE POWER 0 -------------------------------------------------- 11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 929,968 -------------------------------------------------------------------------- 12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] -------------------------------------------------------------------------- 13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.9% -------------------------------------------------------------------------- 14) TYPE OF REPORTING PERSON* OO (Irrevocable trust) -------------------------------------------------------------------------- Page 8 of 14 Item 1. Security and Issuer Common stock of Natus Medical Incorporated, 1501 Industrial Road, San Carlos, CA 94070. Item 2. Identity and Background The D3 Family Fund, L.P., a Washington State partnership, whose principal business is investing in the equities of public micro-cap issuers. Located at 19605 N.E. 8th St., Camas, Washington 98607. No convictions or administrative proceedings. Item 3. Source and Amount of Funds or Other Consideration Source of funds is money invested in the partnership by its partners. Aggregate amount invested in BABY shares purchased by the partnership is $3,929,215. Item 4. Purpose of Transaction The purpose of the share purchases is for investment. None of the other actions described in items 4(a)-(j) are currently contemplated. Item 5. Interest in Securities of the Issuer (a,b) D3 owns, and has sole voting and dispositive power over, 857,400 BABY shares. In addition, 22,600 BABY shares are owned by Haredale; 10,700 by Hildebrandt; 6,300 by Toxford; 2,111 by Mr. Nierenberg personally; and 30,857 by an irrevocable trust for his children. Aggregate ownership is 929,968 (5.9%). (c) D3's transactions in the last 60 days were the following transactions: No. of shares Average Date purchased price ------- ----------- ------------ 2/12 2,700 4.05 2/13 105,200 4.24 2/14 10,700 4.39 2/19 40,000 4.53 2/20 6,900 4.58 2/22 15,000 4.78 2/25 77,000 4.83 2/26 121,800 4.83 2/27 36,000 4.64 2/28 420,000 4.55 3/4 22,100 4.55 (d) N/A (e) N/A Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer N/A Item 7. Material to be Filed as Exhibits N/A Page 9 of 14 Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 3/7/02 /s/DAVID NIERENBERG - ------------------- ------------------------------------ Date David Nierenberg President Nierenberg Investment Management Company, Inc., the General Partner Of The D3 Family Fund, L.P. Page 10 of 14 Item 1. Security and Issuer Common stock of Natus Medical Incorporated, 1501 Industrial Road, San Carlos, CA 94070. Item 2. Identity and Background (a) Haredale Ltd., a Bahamian corporation. (b) P.O. Box N-4465, Nassau, New Providence, The Bahamas. (c) Haredale is in the investment business at the address above. (d) None (e) None (f) The Bahamas. Item 3. Source and Amount of Funds or Other Consideration Source of funds is Haredale working capital. Haredale has invested $104,501 in shares of BABY. Item 4. Purpose of Transaction The purpose of the share purchases is for investment. None of the other actions described in items 4(a)-(j) are currently contemplated. Item 5. Interest in Securities of the Issuer (a,b) Haredale owns, and Mr. Nierenberg has sole voting and dispositive power over, its 22,600 shares. (c) Transactions in last 60 days: No. of shares Average Date purchased price ------- ----------- ------------ 2/19 14,800 4.53 2/25 3,000 4.84 2/26 3,200 4.84 2/27 1,600 4.66 (d) N/A (e) N/A Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer Haredale pays Mr. Nierenberg an annual management fee and a share of its net profits for his personal management of its account. Item 7. Material to be Filed as Exhibits N/A Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 3/7/02 /s/DAVID NIERENBERG - ------------------- ------------------------------------ Date David Nierenberg Authorized to trade for Haredale, Ltd. Page 11 of 14 Item 1. Security and Issuer Common stock of Natus Medical Incorporated, 1501 Industrial Road, San Carlos, CA 94070. Item 2. Identity and Background (a) James Henry Hildebrandt a Canadian citizen resident in Hong Kong. (b) c/o Bain & Company, Tenth Floor, One Pacific Place, 88 Queensway, Hong Kong. (c) Mr. Hildebrandt is a management consultant. (d) None (e) None (f) Canada Item 3. Source and Amount of Funds or Other Consideration Source of funds is working capital. Mr. Hildebrandt has invested $50,867 in shares of BABY. Item 4. Purpose of Transaction The purpose of the share purchases is for investment. None of the other actions described in items 4(a)-(j) are currently contemplated. Item 5. Interest in Securities of the Issuer (a,b) Mr. Hildebrandt owns, and Mr. Nierenberg has sole voting and dispositive power over, his 10,700 BABY shares. (c) Transactions in the last 60 days: No. of shares Average Date purchased price ------- ----------- ------------ 2/21 6,000 4.71 2/26 4,700 4.81 (d) N/A (e) N/A Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer Mr. Hildebrandt pays Mr. Nierenberg an annual management fee and a share of its net profits for his personal management of his account. Item 7. Material to be Filed as Exhibits N/A Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 3/7/02 /s/DAVID NIERENBERG - ------------------ ------------------------------------ Date David Nierenberg Authorized to trade for John Henry Hildebrandt Page 12 of 14 Item 1. Security and Issuer Common stock of Natus Medical Incorporated, 1501 Industrial Road, San Carlos, CA 94070. Item 2. Identity and Background (a) Toxford Corporation, a Channel Islands corporation. (b) P.O. Box 3048, St. Andrews House, Le Bordage, St. Peter Port, Guernsey, Channel Islands, British Isles. (c) Toxford Corporation is in the investment business. (d) None (e) None (f) Channel Islands, British Isles. Item 3. Source and Amount of Funds or Other Consideration Source of funds is Toxford working capital. Toxford has invested $29,903 in shares of BABY. Item 4. Purpose of Transaction The purpose of the share purchases is for investment. None of the other actions described in items 4(a)-(j) are currently contemplated. Item 5. Interest in Securities of the Issuer (a,b) Toxford Corporation owns, and Mr. Nierenberg has sole voting and dispositive power over, its 6,300 BABY shares. (c) Transactions in the last 60 days: No. of shares Average Date purchased price ------- ----------- ------------ 2/21 4,000 4.71 2/26 2,300 4.81 (d) N/A (e) N/A Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer Toxford Corporation pays Mr. Nierenberg an annual management fee and a share of its net profits for his personal management of its account. Item 7. Material to be Filed as Exhibits N/A Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 3/7/02 /s/DAVID NIERENBERG - ------------------ ------------------------------------ Date David Nierenberg Authorized to trade for Toxford Corporation Page 13 of 14 Item 1. Security and Issuer Common stock of Natus Medical Incorporated, 1501 Industrial Road, San Carlos, CA 94070. Item 2. Identity and Background (a) David Nierenberg, a US citizen resident in Washington state. (b) 19605 N.E. 8th Street, Camas, Washington 98607 (c) Investment management. Mr. Nierenberg is a general partner of D3. (d) None (e) None (f) USA Item 3. Source and Amount of Funds or Other Consideration Source of funds is a distribution of BABY shares from Trinity Ventures, a venture capital firm which invested in BABY when it was a private company. Item 4. Purpose of Transaction The purpose of the share purchases is for investment. None of the other actions described in items 4(a)-(j) are currently contemplated. Item 5. Interest in Securities of the Issuer (a,b) Mr. Nierenberg owns, and has sole voting and dispositive power over, his 2,111 BABY shares. (c) Transactions in the last 60 days: No. of shares Average Date purchased price ------- ----------- ------------ 1/15 1,056 N/A 2/27 1,055 N/A (d) N/A (e) N/A Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer N/A Item 7. Material to be Filed as Exhibits N/A Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 3/7/02 /s/DAVID NIERENBERG - ------------------ ------------------------------------ Date David Nierenberg Page 14 of 14 Item 1. Security and Issuer Common stock of Natus Medical Incorporated, 1501 Industrial Road, San Carlos, CA 94070. Item 2. Identity and Background (a) The David and Patricia Nierenberg 1993 Irrevocable Trust, 6/11/93, Lawrence K. Orr, Trustee. (b) Lawrence K. Orr, General Partner, Trinity Ventures, 3000 Sand Hill Road, Bldg. 4, Suite 160, Menlo Park, CA 94025. (c) This is an irrevocable trust for the benefit of the Nierenberg children. (d) None (e) None (f) A California trust. Item 3. Source and Amount of Funds or Other Consideration Source of funds is money invested in the Trust by its Trustors. Item 4. Purpose of Transaction The purpose of the share purchases is for investment. None of the other actions described in items 4(a)-(j) are currently contemplated. Item 5. Interest in Securities of the Issuer (a,b) The Tust owns, and Mr. Orr has sole voting and dispositive power over, its 30,857 BABY shares. (c) Transactions in the last 60 days: None (d) N/A (e) N/A Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer N/A Item 7. Material to be Filed as Exhibits N/A Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 3/7/02 /s/DAVID NIERENBERG - ------------------ ------------------------------------ Date David Nierenberg Authorized to trade for The Nierenberg Family 1993 Trust -----END PRIVACY-ENHANCED MESSAGE-----